Senzime AB (SEZI) - Cash Flow Conversion Efficiency

Latest as of March 2026: -0.081x

Based on the latest financial reports, Senzime AB (SEZI) has a cash flow conversion efficiency ratio of -0.081x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-23.03 Million ≈ $-2.48 Million USD) by net assets (Skr283.50 Million ≈ $30.51 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See SEZI equity financing ratio to measure how much of total assets are equity-financed.

Senzime AB - Cash Flow Conversion Efficiency Trend (2006–2025)

This chart illustrates how Senzime AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Senzime AB (SEZI) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

Senzime AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Senzime AB ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Kredyt Inkaso SA
WAR:KRI
0.105x
3P Learning Ltd
AU:3PL
0.087x
PUBLIC POLICY HO.COM 144A
F:PD7
N/A
Cryomax Cooling System Corp
TW:1587
0.051x
WeGrow AG
DU:ZN2
N/A
Korea Computer & Systems Inc
KQ:115500
0.074x
Kronox Lab Sciences Ltd
NSE:KRONOX
0.090x
Nurminen Logistics Oyj
HE:NLG1V
0.125x

Annual Cash Flow Conversion Efficiency for Senzime AB (2006–2025)

The table below shows the annual cash flow conversion efficiency of Senzime AB from 2006 to 2025. For the full company profile with market capitalisation and key ratios, see Senzime AB (SEZI) total market value.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 Skr304.46 Million
≈ $32.76 Million
Skr-109.10 Million
≈ $-11.74 Million
-0.358x -16.98%
2024-12-31 Skr345.86 Million
≈ $37.22 Million
Skr-105.94 Million
≈ $-11.40 Million
-0.306x -0.97%
2023-12-31 Skr375.48 Million
≈ $40.41 Million
Skr-113.91 Million
≈ $-12.26 Million
-0.303x +41.91%
2022-12-31 Skr261.90 Million
≈ $28.18 Million
Skr-136.78 Million
≈ $-14.72 Million
-0.522x +3.31%
2021-12-31 Skr150.58 Million
≈ $16.20 Million
Skr-81.33 Million
≈ $-8.75 Million
-0.540x -225.94%
2020-12-31 Skr231.35 Million
≈ $24.90 Million
Skr-38.34 Million
≈ $-4.13 Million
-0.166x +0.04%
2019-12-31 Skr163.69 Million
≈ $17.62 Million
Skr-27.14 Million
≈ $-2.92 Million
-0.166x -56.49%
2018-12-31 Skr167.41 Million
≈ $18.02 Million
Skr-17.73 Million
≈ $-1.91 Million
-0.106x -21.04%
2017-12-31 Skr140.46 Million
≈ $15.12 Million
Skr-12.29 Million
≈ $-1.32 Million
-0.088x -15.36%
2016-12-31 Skr131.87 Million
≈ $14.19 Million
Skr-10.00 Million
≈ $-1.08 Million
-0.076x +45.81%
2015-12-31 Skr45.81 Million
≈ $4.93 Million
Skr-6.41 Million
≈ $-690.18K
-0.140x -60.40%
2014-12-31 Skr44.08 Million
≈ $4.74 Million
Skr-3.85 Million
≈ $-414.05K
-0.087x +39.78%
2013-12-31 Skr37.46 Million
≈ $4.03 Million
Skr-5.43 Million
≈ $-584.31K
-0.145x +23.55%
2012-12-31 Skr31.99 Million
≈ $3.44 Million
Skr-6.06 Million
≈ $-652.57K
-0.190x -170.80%
2011-12-31 Skr27.87 Million
≈ $3.00 Million
Skr-1.95 Million
≈ $-209.94K
-0.070x +27.67%
2010-12-31 Skr21.90 Million
≈ $2.36 Million
Skr-2.12 Million
≈ $-228.10K
-0.097x -0.30%
2009-12-31 Skr16.61 Million
≈ $1.79 Million
Skr-1.60 Million
≈ $-172.54K
-0.096x -664.63%
2006-12-31 Skr7.55 Million
≈ $812.29K
Skr129.00K
≈ $13.88K
0.017x --

About Senzime AB

ST:SEZI Sweden Medical Devices
Market Cap
$61.75 Million
Skr573.83 Million SEK
Market Cap Rank
#21037 Global
#383 in Sweden
Share Price
Skr3.65
Change (1 day)
-1.35%
52-Week Range
Skr3.60 - Skr6.81
All Time High
Skr26.50
About

Senzime AB (publ), a medical device company, develops, manufactures, and markets algorithm-powered patient monitoring systems to increase patient safety during and after surgery in Europe and the United States. The company offers TetraGraph, quantitative train of-four (TOF) monitoring refined by real-world patient data; and ExSpiron, a non-invasive monitoring system that uses bioelectrical impeda… Read more